Literature DB >> 11106283

Osteogenesis imperfecta: perspectives and opportunities.

P H Byers1.   

Abstract

The last 2 years have seen additions proposed to the very limited armamentarium of treatments for osteogenesis imperfecta. These include the use of bisphosphonates to decrease bone resorption, growth hormone to augment growth and collagen production, and bone marrow transplantation to create chimeras at the level of the collagen production unit in bone. Although there are optimistic proponents for each strategy, the lack of well-controlled studies and the absence of clearly defined objectives for therapy hinder clear assessment.

Entities:  

Mesh:

Year:  2000        PMID: 11106283     DOI: 10.1097/00008480-200012000-00016

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  3 in total

Review 1.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

Review 2.  Bisphosphonate therapy for osteogenesis imperfecta.

Authors:  Kerry Dwan; Carrie A Phillipi; Robert D Steiner; Donald Basel
Journal:  Cochrane Database Syst Rev       Date:  2016-10-19

3.  Whole-genome sequencing of Atacama skeleton shows novel mutations linked with dysplasia.

Authors:  Sanchita Bhattacharya; Jian Li; Alexandra Sockell; Matthew J Kan; Felice A Bava; Shann-Ching Chen; María C Ávila-Arcos; Xuhuai Ji; Emery Smith; Narges B Asadi; Ralph S Lachman; Hugo Y K Lam; Carlos D Bustamante; Atul J Butte; Garry P Nolan
Journal:  Genome Res       Date:  2018-03-22       Impact factor: 9.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.